Abstract:Background: The complement system is part of the innate immune system that clears pathogens and cellular debris. In the healthy brain, complement influences neurodevelopment and neurogenesis, synaptic pruning, clearance of neuronal blebs, recruitment of phagocytes, and protects from pathogens. However, excessive downstream complement activation that leads to generation of C5a, and C5a engagement with its receptor C5aR1, instigates a feed-forward loop of inflammation, injury, and neuronal death, making C5aR1 a potential therapeutic target for neuroinflammatory disorders. C5aR1 ablation in the Arctic (Arc) model of Alzheimer's disease protects against cognitive decline and neuronal injury without altering amyloid plaque accumulation. Methods: To elucidate the effects of C5a-C5aR1 signaling on AD pathology, we crossed Arc mice with a C5a-overexpressing mouse (ArcC5a+) and tested hippocampal memory. RNA-seq was performed on hippocampus and cortex from Arc, ArcC5aR1KO, and ArcC5a+ mice at 2.7-10 months and age-matched controls to assess mechanisms involved in each system. Immunohistochemistry was used to probe for protein markers of microglia and astrocytes activation states. Results: ArcC5a+ mice had accelerated cognitive decline compared to Arc. Deletion of C5ar1 delayed or prevented the expression of some, but not all, AD-associated genes in the hippocampus and a subset of pan-reactive and A1 reactive astrocyte genes, indicating a separation between genes induced by amyloid plaques alone and those influenced by C5a-C5aR1 signaling. Biological processes associated with AD and AD mouse models, including inflammatory signaling, microglial cell activation, and astrocyte migration, were delayed in the ArcC5aR1KO hippocampus. Interestingly, C5a overexpression also delayed the increase of some AD-, complement-, and astrocyte-associated genes, suggesting the possible involvement of neuroprotective C5aR2. However, these pathways were enhanced in older ArcC5a+ mice compared to Arc. Immunohistochemistry confirmed that C5a-C5aR1 modulation in Arc mice delayed the increase in CD11c-positive microglia, while not affecting other pan-reactive microglial or astrocyte markers. Conclusion: C5a-C5aR1 signaling in AD largely exerts its effects by enhancing microglial activation pathways that accelerate disease progression. While C5a may have neuroprotective effects via C5aR2, engagement of C5a with C5aR1 is detrimental in AD models. These data support specific pharmacological inhibition of C5aR1 as a potential therapeutic strategy to treat AD.

Modulation of C5a-C5aR1 signaling alters the dynamics of AD progression

Astrocyte-Microglia Cross Talk through Complement Activation Modulates Amyloid Pathology in Mouse Models of Alzheimer's Disease.

NFκB-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer's disease.

C5aR1 antagonism suppresses inflammatory glial responses and alters cellular signaling in an Alzheimer's disease mouse model

C5aR1 signaling promotes region‐ and age‐dependent synaptic pruning in models of Alzheimer's disease

C5a Increases the Injury to Primary Neurons Elicited by Fibrillar Amyloid Beta

Complement C3aR Inactivation Attenuates Tau Pathology and Reverses an Immune Network Deregulated in Tauopathy Models and Alzheimer’s Disease

[O1–14–03]: THE ROLE OF COMPLEMENT C3 AND C3AR RECEPTOR IN TAU PATHOLOGY IN ALZHEIMER's DISEASE

Complement C3aR signaling: Immune and metabolic modulation and its impact on Alzheimer's disease

THE ROLE OF COMPLEMENT C3 AND C3AR RECEPTOR IN TAU PATHOLOGY IN ALZHEIMER’S DISEASE

CCR5 regulates Aβ1-42-induced learning and memory deficits in mice

Complement Protein C5a Enhances the Β-Amyloid-induced Neuro-Inflammatory Response in Microglia in Alzheimer’s Disease

The intricate role of CCL5/CCR5 axis in Alzheimer disease

Targeting CCR3 to Reduce Amyloid-β Production, Tau Hyperphosphorylation, and Synaptic Loss in a Mouse Model of Alzheimer’s Disease

The deficient CLEC5A ameliorates the behavioral and pathological deficits via the microglial Aβ clearance in Alzheimer's disease mouse model

Microglial deletion of C1q rescues AD cognitive decline and synaptic loss

Cognitive impairment in Alzheimer's disease FAD 4T mouse model: Synaptic loss facilitated by activated microglia via C1qA

Complement C3aR Depletion Reverses HIF-1-induced Metabolic Impairment and Enhances Microglial Response to A Pathology

Noradrenergic signaling controls Alzheimer's disease pathology via activation of microglial β2 adrenergic receptors

Reduction in GABAB on glia induce Alzheimer's disease related changes

Increased Cysteinyl-Trna Synthetase Drives Neuroinflammation in Alzheimer’s Disease